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Expression of xv integrins and vitronectin receptor
identity in breast cancer cells
T Meyer, JF Marshall and IR Hart
Richard Dimbleby Department of Cancer Research/lCRF Laboratory, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
Summary In the present study we have used fluorocytometry and immunoprecipitation to characterize the expression of av-containing
integrins in a panel of eight human breast cancer cell lines and one normal human mammary epithelial line. We show that the classical
vitronectin receptor avO3 is expressed in only one cell line (MDA-MB-231), whereas avP5 is expressed on all breast cancer cell lines and
av,1 is expressed on the majority. Using adherence assays to purified ligands in the presence and absence of function-blocking monoclonal
antibodies, we have demonstrated that avJ5 mediates adhesion to vitronectin in the majority of these cells. In one cell line, ZR75-1, avp1
contributes significantly to adhesion to immobilized vitronectin. The formation of focal adhesions containing the av and P1 subunits on
vitronectin is also demonstrated by indirect immunofluorescence.
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Breast cancer affects 1 in 12 women in the UK and accounts for
18% offemale malignant disease worldwide. Ofthose who present
with apparently operable disease, more than half will die from
metastatic disease. Understanding the biological mechanisms
underlying the metastatic process is therefore ofmajor importance
in the hope that such understanding will lead to the evolution of
new therapeutic strategies.
Metastasis requires that the disseminating cell disengages from
its primary site, migrates and adheres at a distant site - all
processes dependent on regulated-dysregulated cellular adhesion.
Many of these functions appear to be modulated by integrins, and
there is a growing body of evidence suggesting that variations in
expression of these molecules can have a profound effect upon
tumour biology (Albelda, 1993).
Integrins include a diverse family of heterodimeric cell surface
receptors for constituents of the extracellular matrix (ECM) and
occasionally for other cell-associated adhesion molecules (Hynes,
1987). They are composed ofnon-covalently associated a- and ,-
glycoprotein subunits, andreceptordiversity and ligand specificity
are generated by the various associations of at least eight known
n-subunits and 14 a-subunits.
In recent years, it has become apparent that integrins do not
function merely as transmembrane rivets, linking the cell to the
ECM, but that they are also involved in signalling (Hynes, 1992).
In this way, the extracellular environment can influence cellular
activity during functions as diverse as migration, differentiation
and cell survival.
In the present study we have examined the expression and func-
tion of the av-containing heterodimers in a panel of breast cancer
cell lines. The av subunit has been shown to dimerize with a
variety of ,-subunits, including PI, j83, P5, ,36 and P8 and, with
the exception ofavp6, all these heterodimers have been shown to
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bind to the substrate vitronectin. Some of these receptors have
other ligands, most notably the promiscuous avP3, so that the
composition of the av-containing heterodimers can affect cell
behaviour by determining adhesive interactions.
The nature of the vitronectin receptor is ofparticular interest in
oncology because it has been implicated in tumour progression
and acquisition of invasiveness (Marshall and Hart, 1996). In
melanoma, for example, the expression of avP3 correlates with
invasiveness (Gehlsen et al, 1992) and there is a correlation
between avP3 and tumorigenic capacity (Marshall et al, 1991;
Marshall and Hart, 1996). Recently, there has been evidence of a
close functional inter-relationship between members of the av
subfamily and the uPA/uPAR proteolytic system (Nip et al, 1995;
Stefansson and Lawrence, 1996; Yebra et al, 1996). This is of
particular interest in breast cancer in which uPA (Duffy et al,
1990) and uPAR expression have been shown to correlate with
prognosis (Duggan et al, 1995). Accordingly, as a first step in
elucidating the role of vitronectin receptors in breast cancer, it
seemed important to examine the composition and function of
putative vitronectin receptors, i.e. av-containing heterodimers, in
breast cancer cells. We have used fluorocytometry, immunoprecip-
itation and indirect immunofluorescence to examine the expres-
sion of ocv integrins in a panel of breast cancer cell lines and
identified the dominant vitronectin receptor by performing adhe-
sion assays with function-blocking antibodies.
MATERIALS AND METHODS
Cell lines and tissue culture
All cell lines were obtained from the Central Cell Services at the
Imperial CancerResearch Fund. Eighthumanbreastcancercell lines
were used in this study and were cultured in the following media
supplemented with 10% fetal calf serum (FCS) (GIBCO BRL,
Paisley, UK) and L-glutamine 4 mm. Lines ZR75-1, MDA-MB-231
and MDA-MB 468 were grown in Eagle's minimal essential
medium (EMEM). Lines T47D and BT474 were grown in Roswell
Park Memorial Institute medium (RPMI-1640) supplemented with
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Table 1 Expression of av and ,B1 integrins on the surface of breast carcinoma cell lines determined byfluorocytometry
Integrin subunit or heterodimer
(monoclonal antibody)
Cell av p1 av133 avP5 avP6 avP8
line
P2W7 MAR4 TS2/16 4B7 LM609 23C6 P1F6 P3G2 E7P6 SN1
ZR75 ++ ++1 ++1 ++ + +1 +
T47D ++ ++, ++ ++1 - - + +1
BT20 ++ ++2 ++2 ++ ++
SKBR3 ++ ++ -2 - ++
MB468 ++ ++ ++2 + +
MCF7 ++ ++, ++, ++ - - + + - -
MDA231 ++ ++ ++2 +1 + + ++
BT474 + +, ++ - - + - -
MCF1OA ++ ++ -2 + +
DX3 ++ + ++ ++ +
(melanoma)
Background fluorescence was measured by omitting the primary antibody, and this value was subtracted from the value obtained with the primary antibody to
give a median fluorescence. Cells were considered negative (-) if the fluorescence was less than 5 units; + indicates a fluorescence of 5-50 units and ++ above
50 units. The values were derived from at least three separate experiments unless indicated by a subscript. A melanoma cell line (DX3) has been included as a
positive control for av,B3 that is absent or expressed weakly in the breast cell lines.
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Figure 1 (A) Immunoprecipitation of breast cancer cells. Cell-surface proteins were labelled with 1251, lysed and immunoprecipitated with a monoclonal
antibody against av (L230). L230 co-precipitates a 131 band in all the breast cell lines, in addition to a lower band corresponding in size to the other 1-subunits.
The composition of this band in each case can be inferred from the FACS data. (B) The identity of the putative 13 band is confirmed by immunodepletion in
MCF7 cells that were surface labelled as above and then cleared of ,13-containing heterodimers by serial immunoprecipitation with MAR4. The residual lysate
was then immunoprecipitated with P2W7. Compared with the control, which was depleted with CD31, there has been a significant reduction in the intensity of
the middle band confirming its identity as ,13
insulin (Sigma) at 10 gg ml-'. Line SKBR3 was grown in RPMI-
1640, 10% FCS. Line MCF7 (an insulin-dependent variant) was
grown inEMEM with insulin at20 igml-1 andlineBT20 was main-
tained in MEM. MCF1OA is a cell line established from the
mammary tissue of a woman with fibrocystic disease and is felt to
represent a normal mammary epithelial phenotype (Soule et al,
1990). This was cultured in a 1:1 mixture ofEMEM and Ham's F12
medium supplemented with 5% horse serum (GIBCO), 20 ng ml-'
epidermal growth factor (Sigma), 10 gg ml-1 insulin, 5 mg ml-'
hydrocortisone and 100 ng ml-1 cholera toxin (Sigma). DX3 is a
human melanoma cell line used as a positive control in some
experiments and this was cultured in EMEM with 10% FCS and
L-glutamine.
All cells were grown as monolayers on plastic at 37°C in a
humidified atmosphere of 8% carbon dioxide-92% air. Cells were
subcultured at 70-90% confluency using trypsin 0.25% (w/v)/
EDTA 5 mM to detach cells.
Antibodies
The following mouse monoclonal antibodies were used - anti-xv:
P2W7 (produced in-house), 17E6 (function blocking; a gift from
Dr SL Goodman, E Merck, Germany), L230 (ATCC); anti-p1:
MAR 4 (Dr S Martingnone, Istituto Nazionale perlo Studio e Curio
dei Tumori, Milan, Italy), TS2/16 (ATCC) and 4B7 (in-house),
P4C1O (function blocking; Life Technologies); anti-oxvO3: 23C6
(Professor MA Horton, University College London) and LM609
(Chemicon International, Harrow, UK); anti-avp5: P1F6 (Life
Technologies), P3G2 (Dr D Cheresh, The Scripps Research
Institute, La Jolla, CA, USA); anti-avp6: E7P6 (Dr D Sheppard,
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Figure 2 Adherence of breast cancer cell lines to vitronectin in the presence and absence of function-blocking antibodies. Ninety-six-well plates were coated
with vitronectin at a concentration of 5 9g ml-'. 5'Cr-labelled cells suspended in serum-free medium were plated into the wells and incubated for 1 h at 370C.
The plates were washed to remove non-adherent cells and residual radioactivity measured. The percentage adherence was obtained by calculating the residual
radioactivity as a fraction of the total before washing. Control non-specific binding was estimated from uncoated wells blocked with BSA and is shown in the first
bar. NL and CONT refer to binding in the absence of antibody and the presence of an irrelevant class-matched antibody respectively. The standard deviation
was derived from quadruplicate samples, and each graph is a representative example of an experiment that has been repeated at least three times
University ofCalifornia, San Francisco CA, USA); anti-av8: SNI then washed in ice-cold wash buffer phosphate buffered saline
(Dr S Nishimura, University of California); anti-200-kDa protein: (PBSA)/0.1% bovine serum albumin (BSA)/0.1% sodium azide)
14E2 (Dr S Goodman, E Merck, Germany); anti-a4: 7.2 (in-house); and 50-g1 aliquots, containing 2 x 105 cells, were incubated in a v-
anti-CD31: MEC 13.3 (Dr Vecchi, Mario Negri, Milan). bottomed well of a 96-well plate with a primary monoclonal anti-
body (undiluted supernatant or purified antibody final
concentration 1-20 mg ml-') for 30 min at 4°C. The wells were
Fluorocytometry then washed with wash buffer and incubated with 50 gl of FITC-
Cells were detached with trypsin/EDTA, washed once in complete conjugated rabbit anti-mouse antibody (Dako, Bucks, UK) at a
medium and allowed to remain at 37°C for 30 min. Cells were dilution of 1:40 for 30 min at 4°C. Cells were washed four times
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and resuspended in wash buffer to 400 gl in Falcon 2054 tubes and
analysed by fluorocytometry on a FACScan analyser with consort
30 software (Becton Dickinson, Mountain View, CA, USA). Non-
specific fluorescence was measured by the omission of a primary
antibody and this was ofthe order of5 units (median).
Immunoprecipitation and immunodepletion
Cells were detached using trypsin/EDTA, washed and resuspended
in cold PBSA to a maximum concentration of 107 cells ml'. Cell
surface proteins were then labelled with 1251 using the lactoperoxi-
dase method (Marshall et al, 1991).
Cells were then lysed in ice-cold 1% NP40 buffer at I07 cells ml-1
(20 mm HEPES pH 7.8,1% NP40, 50 mm sodium chloride, 1 mM
calcium chloride, 3 mm magnesium chloride, 0.3 M sucrose,
0.1% sodium azide) to which the protease inhibitors leupeptin
(100 gg ml-'), phenylmethylsulphonyl fluoride (100 ,ug ml-'), apro-
tinin (100 ,ug ml-') and benzamidine (10 mM) were added. Cellular
debris was removed by centrifugation and TCA precipitation
performed to equilibrate the c.p.m. per volume between samples.
This allowed equal amounts of labelled membrane protein to be
loaded into each lane.
Lysates were then incubated on ice with mouse primary antibody
(neat supernatant or purified at 1-20 mg ml' final concentration)
for 15 min followed by 10 ml of rabbit anti-mouse IgG (Dako) for
10 min and finally 50 ml of protein A-Sepharose (Pharmacia,
Milton Keynes, UK; 50% suspension with NP40 Lysis buffer). This
mixture was tumbled overnight at 4°C and the precipitated
complexes washed with a series ofhigh-salt or high-detergent wash
buffers to reduce non-specific binding (Marshall et al, 1991).
Immunoprecipitates were run on a 6% SDS-PAGE gel under non-
reducing conditions, and the gel was dried and autoradiographed.
In immunodepletion experiments, four immunoprecipitation
cycles were performed with one primary antibody before immuno-
precipitating with a second primary antibody.
Adhesion assays
The wells of96-well plates (Falcon 3912; Beckton Dickinson, NJ,
USA) were coated with vitronectin (Life Technologies or
Combined Biomedical Products) at a concentration of5 gg ml-' in
PBSA and incubated for 90 min at 37°C or overnight at 4°C. The
plates were then washed twice with PBSA and flooded with PBSA
containing 0.1% BSA to block residual binding sites and incubated
at 37°C for a further 60 min.
Cells were detached with trypsin/EDTA, resuspended in complete
medium and labelled with 5lCr (Marshall et al, 1991). After washing
three times in serum-free medium, the cells were added to quadrupli-
cate wells (50-,ul aliquots; 2 x 104cells). In the inhibition ofadhesion
assays, 25 jl ofantibodies (diluted to 1:50) were added to the wells.
The antibody-cell mixture was followed by 25-,ul volumes of cell
suspension containing 2 x 104 cells allowed to sit on ice for 10 min
before proceeding with the assay cells. The plates were then incu-
bated at 37°C for 60 min and unbound cells were removed by
immersion and agitation in PBSA twice. Individual wells were then
separated and bound radioactivity counted using a gamma counter
(1261 Multigamma; LKB Wallace, Bromma, Sweden.) Input
radioactivity was measured using reserved 50-,ul aliquots of labelled
cells, and background binding was measured by incubating cells in
uncoated wells that had been blocked with the BSA solution only.
Immunofluorescence
Sterile 13-mm coverslips were placed in the wells of a 24-well
plate; 500 gl of cell suspension (2 x 105 cells ml-') was added to
the wells and incubated at 37°C. Morphology of the cells on the
different substrates was examined by precoating the coverslips
with various ECM proteins and adding the cells in a serum-free
medium.
At certain time intervals thereafter, the coverslips were washed
with 0.1% BSA in phosphate-suffered saline (PBS) and fixed in
1:10 formalin for 1O min. Cells were then incubated in 0.1% Triton
X for 10 min and incubated with the primary antibody at 4'C for
45 min. They were then washed and incubated with FITC-labelled
rabbit anti-mouse antibody. After further washing, the coverslips
were mounted onto glass slides and examined with a fluorescence
microscope (Zeiss Axioplan, Zeiss Microscopes, Welwyn Garden
City, UK).
RESULTS
Fluorocytometry
The surface expression ofav-containing heterodimers was analysed
by fluorocytometry. Table 1 summarizes thequalitative results ofthis
analysis and illustrates some degree of heterogeneity of expression
between the different cell lines. There are, however, common
patterns of expression. Thus, all breast cancer cell lines express
the ctv and [1 subunit and the cxv[5 heterodimer. The classical
vitronectin receptor av33, which is strongly expressed on the
melanoma positive control DX3, is only expressed by one out ofthe
eight breast cancer cell lines, MDA-MB-231, and then only at a
relatively low level. The axv[6 heterodimer is strongly expressed
in BT20 cells but only weakly in ZR75-1, MDA-MB-468 and
MCF1OA lines, while axvf8 is only detected on MDA-MB-468 cells.
Immunoprecipitation
Breast cell lines were surface labelled with 1251, lysed and immuno-
precipitated with L230 (anti-av) as the primary antibody. Figure
1A shows the results of such an immunoprecipitation. The need to
expose the film long enough to detect signal from the cells
expressing lowest levels of these molecules has led to substantial
overexpression of such strongly positive cells as the BT20 and
MCF7 cell lines. However, it can be seen that, in six of the eight
breast cancer cell lines, at least two other proteins are co-immuno-
precipitated. The size of the upper band corresponds to that of the
axv subunit, while the middle band runs at the same rate predicted
for the [1 subunit. The lower bands correspond in electrophoretic
mobility to that expected from other [-subunits, including [3, [5,
[6 and 18. In this experiment, the [31 is not clearly seen in the
SKBR3 or BT474 lanes, suggesting that it is only weakly expressed
in these cells. The normal breast cell line MCF1OA expresses high
levels ofav, but again the [1 band is relatively weak.
That the band running in the [1 position indeed was [31 was
confirmed in two of the cell lines, MCF7 and MDA MB468, by
immunodepletion experiments. In these experiments (Figure 1B),
the lysate was cleared of all [3-containing heterodimers by serial
immunoprecipitation with an anti-5P1 antibody (MAR 4). The
experiment shown used the MCF7 cell line. The lysate was
divided in two; one half was immunoprecipitated four times
with MAR4 and the other immunoprecipitated four times with a
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Figure 3 Indirect immunofluorescence in two breast cancer cell lines. Cells were incubated on coverslips precoated with vitronectin at a concentration of
5 ig ml'. The av and ,13 subunits were then visualized by fluorescence microscopy using P2W7 and 4B7, respectively, as primary antibodies and a fluorescein-
tagged secondary antibody. (A) MCF7 and 4B7. (B) MCF7 and P2W7. (C) ZR75 and 4B7. (D) ZR75 and P2W7. Focal adhesions are indicated by arrows
class-matched control antibody MEC13.3. The cleared lysates
were then immunoprecipitated with P2W7 (anti-av). It is clear
from the illustration that, while the upper (ocv) band and lower
bands are of equivalent intensity, the signal for the middle band
has been reduced significantly by pre-clearing the 5l integrins
with MAR4 relative to the three bands observable in the MEC
13.3-cleared lysates (Figure lB). This provides strong immuno-
logical evidence that the middle band indeed is P1.
These data, together with the FACS data, indicate that av35 is
expressed on all epithelial breast cancer cell lines examined and
that cxvjl is expressed on the majority.
Adhesion to vitronectin
The classical vitronectin receptor acvP3 is not expressed by the
majority of breast cancer cells, although both ocvP5 and cxvpl1,
which have been reported as mediating vitronectin binding
(Cheresh et al, 1989; Bodary and McLean, 1990), are expressed
by these cells. Adhesion assays were performed to ascertain the
identity of the dominant vitronectin receptor.
In Figure 2 representative examples of adhesion assays on
vitronectin substrates are shown. All the breast cancer cell lines
bound to vitronectin with between 20% and 70% of added cells
adhering within the time span of the experiment. The 'normal'
MCFIOA cell line bound most poorly, with fewer than 10% of
added cells adhering over the 60-min period of the assay. In all
breast cancer cell lines examined, with the exception of BT20,
adhesion was reduced significantly by the presence of the oxv-
blocking antibody 17E6 (Figure 2). In all cases, except ZR75-1, a
similar degree of inhibition was achieved using theavP5-blocking
antibody P1F6. For ZR75-1 cells, the 11-blocking antibody P4C10
was required in addition to P1F6 to achieve equivalent inhibition to
that achieved with 17E6 alone. It seems, therefore, that the domi-
nant vitronectin receptor in these tumour cells is cxvI35, although
(Xvl1 appears to contribute significantly to this binding activity in
ZR75-1 cells. The adhesion of BT20 to vitronectin is not signifi-
cantly diminished by the antibodies used, raising the possibility of
alternative receptors. It is notable that other non-integrin receptors,
such as uPAR, have been shown to bind to vitronectin in some cells
(Wei et al, 1994), and this may be relevant here. MCF1OA binds
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very weakly to vitronectin (8.2% adhesion to vitronectin compared
with 4.2% adhesion to BSA; P = 0.05, Mann-Whitney test), even
though itexpressesavP5 albeit at low levels. The addition of 1 mM
Mn2 , which is known to activate integrins, increases adhesion
two- to threefold, and this increase can be inhibited by 17E6 (data
not shown). Variation in the relative activation status of these
receptors in different cell lines may explain why there is no clear
correlation between the level ofintegrin expression and the level of
adhesion.
Distrubution of integrin subunits in cells adherent to
vitronectin
The pattern of integrin expression in response to vitronectin was
examined by indirect immunofluoresence. Coverslips were
precoated with vitronectin at a concentration of 5,g ml-'. Cells
were incubated at 37°C for 4-24 h and labelled with primary anti-
bodies directed against various integrin subunits. A fluorescein-
conjugated secondary antibody was then used to visualize integrin
distribution. In several cell lines a distinct pattern was seen. Figure
3 shows MCF7 and ZR75-1 cells plated on vitronectin and then
labelled for xv and PI. These subunits are distributed in focal
plaques suggesting that, in addition to mediating adhesion and
spreading, they may be involved in signalling. The ,1 integrin in
PI-positive focal adhesions on vitronectin is probably av,Bl,
although the absence of a heterodimer-specific reagent for this
integrin rules out definitive confirmation. However, apart from
avfl, the only other cxJl integrin reported to bind vitronectin is
a81I (Schnapp et al, 1995). Antibodies to a8 were not available
for this study. However, as blocking av with 17E6 abrogated
adhesion of ZR75-1 and MCF7 to vitronectin, 08S1, if present, is
unlikely to contribute to adhesion on vitronectin. In contrast,
blocking both avP5 and f1 resulted in a greater inhibition of
adhesion to vitronectin than blocking avP5 alone (Figure 2),
suggesting that a PI integrin also contributes, albeit weakly, to
vitronectin adhesion in breast carcinoma cells.
The avP5 heterodimer may also contribute to the av plaques,
although we were unable to confirm this using P1F6 as the
primary antibody because ofpoor staining.
The adhesion assays clearly showavP5 to be the major receptor
mediating adhesion to vitronectin, yet the immunofluoresence
suggests that avpl is responding to vitronectin and possibly
initiating signals in the absence of strong adhesion.
DISCUSSION
We have shown in the present studies that the classical vitronectin
receptor exvP3 is expressed in only one of the eight breast cancer
cell lines examined. Rather, the major vitronectin receptor in this
neoplastic cell type is the avP5 heterodimer, which is expressed
by all cells and is generally responsible for adhesion to vitronectin.
The axvpl heterodimer is expressed by most tumour cells exam-
ined but relatively weakly expressed in the only normal breast cell
line, MCF1OA, used in these studies.
Several immunohistochemical studies have examined the
expression of integrins in breast cancer compared with that in
normal breast tissue. (D'Ardenne et al, 1991; Koukoulis et al, 1991;
Pignatelli et al, 1992). The overall impression from these diverse
reports is that the expression of most subunits is down-regulated.
One exception to this is the av subunit, whose expression appeared
to be increased in at least one study (Pignatelli et al, 1992). This did
not correspond to an increased expression in av133, implying that
another av-containing heterodimer(s) may be associated with this
cancer type. The shortcomings of these immunohistochemical
studies are that these data frequently refer to the presence of
integrin subunits rather than heterodimers, and no inference
can be made regarding the functional status ofthe receptors.
A recent study using colorectal cancer cell lines also found
avP5 to be expressed by all neoplastic cells studied with variable
expression of av,B3 and av13l levels (Agrez et al, 1996). No func-
tional analysis was performed in this report but it may be that
av135 is the dominant vitronectin receptor in cells of epithelial
lineage. This is in marked contrast to stromal and endothelial cells
that express av133. The fact that this has not been reported widely
is probably indicative of the relative paucity of studies using
epithelial cell lines to examine the mechanics ofcell adhesion.
Although avP5 mediates adhesion to vitronectin, these cells do
not migrate on vitronectin in serum-free medium (unpublished
observations). Recently, it was reported that the migration of
MCF7 cells on vitronectin can be induced by insulin-like growth
factor type 1 and that this can be blocked with the addition of
PlF6 (anti-av,B5) (Doerr and Jones, 1996). This suggests that the
expression of av135 by epithelial cells is necessary but not suffi-
cient for motility. Interestingly, in a human pancreatic cell line,
Yebra et al (1996) have shown recently thatavP5-mediated migra-
tion on vitronectin requires the presence of receptor-bound
urokinase-type plasminogen activator (uPA), which itself is
induced by transforming growth factor alpha (TGF-x) or phorbol
ester. It will be of interest to see whether a similar relationship
exists in breast cancer cells in the light ofourcategorization ofthe
nature of the vitronectin receptor and the importance of uPA as a
prognostic factor in breast cancer.
We have also demonstrated the apparent ubiquity of av13l
expression in breast cancer cells. The ligand specificity of this
receptor seems to vary depending on the cell type. In malignant
melanoma (Marshall et al, 1995) and human embryonic kidney
cells (Bodary and McLean, 1990), it mediates adhesion to
vitronectin whereas, in neuroblastoma cells, fibroblasts and
glioblastoma cells, it appears to mediate adhesion to fibronectin
(Vogel et al, 1990). In breast cancer itdoes not appear to contribute
to vitronectin binding, except perhaps in ZR75-1 cells. The
absence of a monoclonal antibody to this heterodimeric receptor
hampers its further study, particularly in immunohistochemistry.
Gui and colleagues (Gui et al, 1995) did report the loss of av13l
with lymph node metastasis in mammary carcinoma, but this was
inferred from subunit density and may not represent the true
expression of the heterodimer as 11 is a component of many
different heterodimers. Our own observation that Xvpl expression
is very weak or possibly lacking in MCF1OA is intriguing not only
because it is the only 'normal' cell line examined but also because
it manifestly expresses both the (xv and 1P subunits in abundance.
Why these subunits associate in some but not other cell types is
unclear. Certainly further work needs to be done on this receptor to
understand what governs its expression and to identify its ligand
specificity and function in breast cancer.
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